The field of cancer treatment research has witnessed considerable advancements over recent years, with certain groundbreaking developments catching the public's attention due to their potential impact on patient care and treatment efficacy. Among these developments is the news from OBI Pharma,
In a transformative event that captured attention across the life sciences and fintech communities, the industry's top leaders convened to tackle the pressing issue of funding challenges faced by early-stage life science companies. With substantial investments required for developing new
Eli Lilly has partnered with Alchemab for a significant expansion in amyotrophic lateral sclerosis (ALS) research. This collaboration involves the licensing of ATLX-1282, an innovative antibody that holds promise for future human testing. ALS, a neurodegenerative disease, represents a complex
Amid growing concerns over declining public support and government backing for cancer research, the recent advocacy event provided a significant platform for addressing these challenges. Gathered at a pivotal conference, key figures from the cancer research community, including renowned scientists
How much could life change for those living with severe skin diseases like recessive dystrophic epidermolysis bullosa (RDEB)? An estimated 200,000 people worldwide confront the daunting challenges of epidermolysis bullosa, a rare inherited disorder that leads to fragile skin and painful wounds.
The world of U.S. biomedical research faces formidable challenges as budget cuts pose a graver risk to scientific progress than ever before. A startling revelation in the form of financial reductions has left many researchers questioning the future of some of the nation’s most critical medical a
